Investor Relations

News Releases

Date Title and Summary Additional Formats
Toggle Summary Anika Announces FDA 510(k) Clearance for its WristMotion® Total Arthroplasty System for the Replacement of Painful Wrist Joints
System designed to alleviate pain and restore function and mobility of the wrist joint BEDFORD, Mass. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic
View HTML
Toggle Summary Anika Announces Appointment of Jack Henneman and Stephen Richard to Board of Directors
Board Chair Joseph Bower ,   D.B.A. announces intention not to stand for re-election at 2021 Annual Meeting Jeffery Thompson succeeds Dr. Bower as Chair of the Board BEDFORD, Mass. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation,
View HTML
Toggle Summary Anika to Participate in Upcoming Virtual Investor Conferences
BEDFORD, Mass. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions company with products across the orthopedic early intervention continuum of care, today announced that Cheryl R.
View HTML
Toggle Summary Anika Appoints Michael Levitz as Chief Financial Officer
Seasoned financial executive brings broad medical device industry experience and track record of value creation BEDFORD, Mass. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions company with
View HTML
Toggle Summary Anika Reports Second Quarter 2020 Financial Results
Increased Total Revenue 1% Year-over-Year to $30.7 Million Accelerated the Commercial Integration of Parcus Medical and Arthrosurface Organizations Launching Seven FDA-Cleared Orthopedic and Sports Medicine Products Through Q3 2020 BEDFORD, Mass. , July 30, 2020 (GLOBE NEWSWIRE) -- Anika
View HTML
Toggle Summary Anika To Launch Six FDA-Cleared Sports Medicine and Extremities Products in Third Quarter of 2020
Innovative Products Designed to Meet Needs of Surgeons and their Patients in Joint Preservation and Restoration Procedures BEDFORD, Mass. , July 20, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions
View HTML
Toggle Summary Anika to Issue Second Quarter 2020 Financial Results and Business Highlights on Thursday, July 30
BEDFORD, Mass. , July 16, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation, restoration and regenerative solutions company with products across the orthopedic early intervention continuum of care, today announced that the Company plans to
View HTML
Toggle Summary Anika Announces Planned CFO Transition
Sylvia Cheung to Step Down in August 2020   Company Initiates Search for Successor BEDFORD, Mass. , June 02, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products across the orthopedic early
View HTML
Toggle Summary Anika to Participate in 2020 UBS Virtual Global Healthcare Conference
BEDFORD, Mass. --(BUSINESS WIRE)--May 12, 2020-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company, today announced that Cheryl R. Blanchard , Ph.D., President and Chief Executive Officer, and Sylvia Cheung , Chief Financial Officer,
View HTML
Toggle Summary Anika Reports First Quarter 2020 Financial Results
Total Revenue Increases 43% Year-over-Year Continued Progress on Integration of Parcus Medical and Arthrosurface Acquisitions Withdrawing Full Year 2020 Financial Guidance Well Positioned to Manage through COVID-19 Pandemic BEDFORD, Mass. , May 07, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc.
View HTML